Summary
Introduction
Zidovudine is a nucleoside analogue which inhibits viral replication. It has proved to be beneficial in HIV-1 infection and it is currently widely used in different stages of the disease (Volverding et al, 1990; Hirsch el al., 1993; Sande et al., 1993) . Among its suspected side effects are (i) an acquired and reversible form of myopathy characterized by weakness and myalgia, (ii) the presence of mitochondrial abnormalities (revealed by muscle biopsy), and (iii) a depletion of mtDNA in muscle fibres (Helbert et al., 1988: its inhibition by ZDV has been considered to be the cause of the myopathy.
On the other hand, histological mitochondrial abnormalities have also been found in biopsies of HIV-1 patients untreated with ZDV (Simpson et al., 1993) . The patients in whom mtDNA depletion was identified were all investigated because of the presence of neuromuscular symptoms (Arnaudo et al., 1991) and it can be argued that it is not easy to discriminate between the secondary effects of ZDV and other HIV-1 related myopathies (Till et al., 1990; Simpson et al., 1993) . Further, a correlation between doses of ZDV and mtDNA depletion was not found (Arnaudo et al., 1991) . For all these reasons some authors considered ZDV not to be the cause of the majority of effects attributed to its administration, which intensifies the debate on the effects of ZDV on muscle tissue (Simpson et al., 1993 (Simpson et al., , 1994 Dalakas, 1994; Gherardi et al., 1994; Grau et al., 1994; Kieburtz, 1994) .
We present muscle mtDNA analyses from a group of HIV-1 positive patients who were not specifically studied for neuromuscular complaints, either treated or not with ZDV. We compared the results with those obtained in a group of HIV-1 negative patients suffering from various neuromuscular disorders and with those of another group of normal controls. The aim was to test whether ZDV systematically causes mtDNA abnormalities and, if so, if they can be considered the cause of the neuromuscular dysfunction.
Patients and methods
Patients infected with HIV-1, who had been admitted to a general internal medicine ward were asked to participate in a study to ascertain the effects of ZDV on skeletal muscle, regardless of their medical complaints (Grau and Casademont, 1993) . The protocol was approved by the Hospital Clinic i Provincial ethical committee and all the patients and control subjects gave informed written consent to participate. In the present study we only considered patients who were not admitted in order to study a neuromuscular disorder, and either had been receiving ZDV until at least 1 month before admission, or had never received ZDV. They underwent a complete clinical evaluation, including lifetime cumulative dose of ZDV, if any. A thorough muscular examination included the measurement of muscle strength in the nondominant deltoid muscle with a myometer (Penny and Giles Sensors, Systems Ltd, Christchurch, UK) and an open surgical biopsy. Two groups of control patients were analysed: (i) patients suffering from diverse neuromuscular diseases who underwent muscle biopsy for diagnostic purposes; (ii) patients who underwent an orthopaedic surgical procedure for fortuitous fracture of the femur. All the biopsies analysed were obtained from vastus lateralis. Muscle biopsies were processed for standard histochemical and resin-embedded procedures, and a fragment of each muscle biopsy was used for DNA studies.
Whole DNA was extracted from muscle following standard procedures. Mitochodrial DNA was linearized by digestion (Arnaudo et al., 1991) . To quantify the proportion of nDNA and mtDNA, autoradiographies were scanned with a Preference/DVS-1500 densitometer (Sebia, Paris, France). To validate this method for measurement of mtDNA depletion, two standard curves were constructed: one with 3000 ng of DNA obtained exclusively from a nuclear pellet (i.e. pure nDNA), and increasing concentrations of mtDNA (0-80 ng per sample) obtained from a mitochondrial pellet. The other with total DNA obtained from a normal control (with its nDNA and mtDNA), and increasing concentrations of mtDNA (0-40 ng per sample). In both cases the regression analysis between autorad signal and mtDNA concentration gave an r > 0.95 indicating that both parameters were directly and linearly related, and suggesting a minimal variability between measurements. Two Southern blots were performed for each sample and, in each, the autorad signal was measured three times. Three normal controls were included in each Southern blot. The mean autorad densitometric ratio of mtDNA:nDNA of these controls was considered the baseline for the Southern blots, and the percentage of mtDNA in each patient was obtained in relation to it. In this way the variability due to hybridization conditions, e.g. variation in probe specific activity, was avoided. The figures included in the analyses were the mean of the six measurement for each sample.
Several pairs of primers (Table 1) were subsequently used to amplify regions of mtDNA by PCR using two methods. In one, the conditions utilized and the primers chosen (at least 3700 bp apart) were such that no PCR product could be generated unless there was a population of deleted mtDNA. In the other we used the Expand™ long template PCR system (Boehringer, Mannheim, Germany) to perform long PCRs. Reactions without DNA and with DNA from normal controls were included for each experimental condition. Polymerase chain reaction products were analysed on 0.8-1.5% agarose gels. Fragments identified as shorter than the expected size were run on 5-8% polyacrylamide gels, excised out from the gel, reamplified with the same primers and purified using a Qiaquick spin PCR purification kit (Qiagen Inc, Chatsworth, Calif., USA). Direct automatic sequencing was performed using 3.5 pmol of primers with a Taq Dye Deoxy™ terminator sequencing kit (ABI, Foster City, Calif., USA; number 401113) according to the manufacturer's recommendations. Sequencing primers were those used in the previous PCR amplifications. Polymerase chain reaction sequencing conditions were: denaturation at 96°C for 30 s, annealing at 50°C for 30 s and extension at 60°C for 4 min for 28 cycles. Data analyses were performed with Collection and Analysis computer programs from ABI. The currently known point mutations causing MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes), MERF (myoclonic epilepsy, ragged-red fibres) and NARP (neuropathy, ataxia, retinitis pigmentosa) syndromes were ruled out as previously described (Goto et ah, 1990; Holt et ah, 1990; Shoffner et ah, 1990 
Results
Forty-two HIV-1 infected patients, who fulfilled the ZDVintake requirements for inclusion in the study, were biopsied. The clinical characteristics and biopsy findings of some of them have already been reported (Grau and Casademont, 1993) . Twenty-seven of the 42 HIV-1 positive patients had been receiving ZDV treatment (ZDV+ group) until at least 1 month before biopsy. The ZDV mean lifetime cumulative dose was of 269±143 g. The patients in this group were further categorized depending on the following: (i) presence of muscle weakness or myalgia; (ii) muscle strength <15 N in the nondominant deltoid muscle; or (iii) serum CK levels >200 IU/1 (normal values 33-140 IU/1) ( Table 2 ). Thirteen patients fulfilled at least one of the above criteria and were considered as the 'symptomatic' group, although the symptoms were minimal: only four patients complained of muscle weakness, one of them with myalgia and another had a serum CK of 234 IU/1. In these four patients the data were obtained during the medical evaluation, but were not the reason for their admission to hospital. The remaining HIV+/ ZDV+ patients (n = 14) were included, from a neuromuscular point of view, in an 'asymptomatic' group. There were 15 patients who had never received ZDV (ZDV-group). The most important clinical parameters of all patients, together with the characteristics of the 10 normal controls are shown in Table 2 . The diagnoses for the 12 HIV-1 negative patients with neuromuscular disorders and their ages are presented in Table 3 . Ragged-red fibres were more frequent, but not exclusive to ZDV+ groups (48% versus 7%; P < 0.01). There was also a significant difference between symptomatic and asymptomatic patients (69% versus 28%; P < 0.05) ( Table 2) .
On Southern blot analyses, mtDNA was found to be reduced in HIV-1 positive patients treated with ZDV, both symptomatic and asymptomatic, compared with normal controls (P < 0.005 for both) (Fig. 1) , and also compared HIV-/ZDV-HIV+/ZDV-H1V+/ZDV+ ASYMPTOMATIC SYMTOMATIC % of mtDNA with respect to normal controls patients (not significantly different from ZDV+ group). A similar proportion of patients in the group suffering from diverse neuromuscular disorders was found to be harbouring deletions (33%; not significantly different from HIV-1, ZDV + group), whilst in the normal control group no deletions were found. In the majority of patients studied, mtDNA deletions were poorly represented. By Southern blot analysis, only one deletion in an asymptomatic HIV+/ZDV+ patient was found, the other deletions only being detectable by PCR. The five PCR fragments that were most common in HIV-1 infected patients were reamplified and sequenced (Fig. 4) . All five deletions were flanked by short perfect or imperfect direct repeats of 3-6 bp (Fig. 4, in parenthesis) . with HIV+/ZDV-patients (P < 0.005 and P < 0.001, respectively). Moreover, symptomatic patients had lower levels of mtDNA compared with those who were asymptomatic (54±41 versus 28±20; P < 0.05). We did not find, on the contrary, a correlation between the cumulative dose of ZDV and the decrease in mtDNA (Fig. 2) . The decrease in mtDNA in relation to other variables, such as duration of disease from diagnosis and CD4 count, did not reach statistical significance. The percentage of mtDNA in patients not treated with ZDV ( Fig. 1 ) and in HIV-1 negative patients with diverse neuromuscular disorders did not differ from controls. The level of mtDNA in the three ZDVsymptomatic individuals was within 1 SD of normal controls (-3, +2 and + 7%, respectively). All the patients with raggedred fibres, except the patient in the ZDV-group, had at least a 20% reduction in mtDNA (Fig. 2 ).
By PCR, using different combinations of primer pairs, a series of fragments indicating the presence of deletions (Fig.  3 and Table 4 ) were obtained in HIV-1 infected patients. Thirty-seven percent of the ZDV-treated patients were found to have deletions (present in both symptomatic and asymptomatic patients in this group) and 33% in ZDV-
Discussion
The effect of ZDV on skeletal muscle has generated many debates (Simpson etal, 1993 (Simpson etal, , 1994 Dalakas, 1994; Gherardi et al, 1994; Grau et al, 1994; Kieburtz, 1994) , but the majority of authors currently believe that ZDV can be considered to be the cause of the so called 'ZDV myopathy' (Helbert et al, 1988; Dalakas et al., 1990; Grau and Casademont, 1993; Cupler et al., 1995; Sinnwell et al, 1995) . Such myopathy seems to be related to the intake of elevated doses of ZDV for a prolonged period of time, and it has proved to be partially reversible after the discontinuation of the drug (Dalakas et al, 1990; Chalmers et al, 1991; Mhiri et al, 1991) . The protective effect of L-carnitine demonstrated in an experimental model with human myotubes (Sandstrom et al, 1987; Semino-Mora et al, 1994a, b ) has yet to be proven clinically. Arnaudo et al (1991) found that patients suffering from ZDV myopathy had lower than normal levels of mtDNA in their muscle fibres. In the present study we demonstrate that such a reduction is also present in asymptomatic patients treated with ZDV for a relatively prolonged period of time, and that it seems to be more marked in patients who present with weakness, myalgia, raised CK, or a combination of these. A significant percentage of patients taking ZDV had ragged-red fibres or 'ZDV fibres' (Grau et al, 1994) on histochemical analysis. Ragged-red fibres have been demonstrated to be a consequence of the depletion of mtDNA (Lamperth et al, 1991; Tritschler et al, 1992) and have been found to be more frequent in symptomatic than in asymptomatic patients. Such findings suggest that ZDV is directly responsible for the mtDNA depletion. Since the number of symptomatic patients is low, especially in the ZDV-group, the results also suggest that muscle dysfunction is a direct consequence of ZDV treatment, beginning at a morphological level and, if exposure to it continues, expressed later clinically. The alternative explanation, i.e. that degenerated fibres with membrane debris were mistaken for ragged-red fibres, and that muscle necrosis and degeneration secondarily depleted mtDNA (Poulton et al., 1995) , can be ruled out because the group of patients with diverse neuromuscular diseases, some of them needed by mitochondria to proliferate effectively is unknown, it is possible that after the discontinuation of ZDV a rapid proliferation of mitochondria could overcome the depletion in some patients. The second possible explanation is that patients who follow medical instuctions strictly and take ZDV every 6 h precisely, are more prone to mtDNA depletion than others less compliant. This could be explained in terms of the very short half-life of ZDV (Sandstrom et al., 1987) . Hence, compliant patients would have constant significant serum levels of ZDV, whilst less compliant patients allow levels to drop by leaving >6 h gaps between doses thus enabling DNA polymerase to act and replenish mtDNA.
In the present study we further analysed the eventual effects of ZDV on the mtDNA genome. The most common point mutations described in mitochondrial diseases were absent (Goto et al., 1990; Holt et al., 1990; Shoffner et al., 1990) . On the other hand, we found deletions in 37% of the patients receiving ZDV, which was similar to HIV-1 infected patients who had never received ZDV (33%), and to other HIV-1 negative patients suffering from a series of neuromuscular disorders (33%), while no deletions were found in normal controls. Such findings reasonably exclude that deletions were a consequence of ZDV intake and makes it improbable that they were due to HIV-1 infection itself. It is currently known that mtDNA deletions are relatively frequent in older people, a fact that has been attributed to the deleterious effect of oxidative stress on the mitochondrial genome with increasing age (Cortopassi et al., 1990; Arnheim et al., 1992) . It can be hypothesized that other scenarios where oxidative stress would be suspected, e.g. long-standing infection, intercurrent diseases, nutritional deficiency, drug abuse and chronic neuromuscular disorders, could also be associated with the presence of mtDNA deletions. The appearance of deletions can be explained by the presence of short direct repeats flanking the deleted fragments (Schon et with severely necrotic muscle, showed no reduction in mtDNA.
An interesting aspect of the effect of ZDV on muscle tissue, also found by Arnaudo et al. (1991) , is a lack of the expected correlation between doses of ZDV and mtDNA depletion. Two possible explanations can be offered. The first is that some patients were withdrawn from ZDV when investigated and treated for intercurrent diseases, such that some of our patients were on ZDV at the moment of biopsy and others were not. Moreover, in this latter group, there was a variable time between the cessation of ZDV and muscle biopsy, ranging from ! to 17 days. As the exact time (Anderson et al., 1981) . Deleted fragments are indicated in parenthesis, and direct repeats are in bold type. On the right the nucleotides 5' and 3' limiting the deletions are shown with the length of the deletion in parenthesis. Shoffner etal, 1989) . Such structures may facilitate homologous recombination or slipped misspairing of mtDNA in the presence of the polymerase inhibitor ZDV. An important aspect is that deletions, except in one patient, were detectable only by PCR, not by Southern analysis. This implies that the proportion of deleted DNA was low. Although the exact proportion necessary for clinical expression is unknown, it is generally accepted that it has to be relatively high. At least in classical mitochondrial diseases the proportion is usually higher than 50% (Schon et al., 1989; Shoffner et al, 1989; Wallace, 1993) . Under such circumstances, we believe that the deletions found in our patients were of questionable significance from a pathogenetic point of view.
We conclude that ZDV taken for a sustained period of time produces a decrease in mtDNA, evert in patients completely asymtomatic from a neuromuscular point of view. The presence of histological alterations is a consequence of such intake that, if maintained, can be expressed as a clinical muscular dysfunction. Deletions of mtDNA, also found in patients treated with ZDV, are possibly related to other circumstances also present in such patients, but not to ZDV itself. While awaiting the results of clinical trials testing the possible protective benefits of L-carnitine, and in view of the present findings, maybe a wash-out period in ZDV treatment, eventually substituting another antiretroviral drug that does not inhibit yDNA polymerase, would be advisable to avoid the deleterious effects of ZDV on mitochondrial genome.
